1UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [ J ]. BMJ, 1998, 317(7160) :703-713.
2Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus ( the ADVANCE trial) : a randomised controlled trial [ J ]. Lancet,2007,370(9590) :829-840.
3Voyaki SM, Staessen JA, Thijs L, et al. Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension [ J ]. J Hypertens,2001,19(3) :511-519.
4Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events [J]. N Engl J Med, 2008, 358 ( 15 ) : 1547-1559.
5Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and metaanalysis [ J ]. Lancet, 2005, 366 ( 9502 ) : 2026-2033.
6Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes[J]. N Engl J Med,2001,345(12) :851-860.
8Tohgi H,Kawashima M,Tamura K,et al.Coagulation-fibrinolysis abnormalities in acute and chronic phases of cerebral thrombosis and embolism[].Stroke.1990
